GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Colinz Laboratories Ltd

Colinz Laboratories approves Q1 FY26 results and appoints new directors

BOARD ▲ Positive Development LOW RISK
📅 Filed on BSE: 30 Jul 2026, 05:50 PM IST  ·  BSE ID: e42724a3-3467-4b8d-b63c-19550b598d6a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board met to approve financial results, reports, and key leadership appointments, setting the date for its annual meeting.
🤖 AI Summary
  • Colinz Laboratories approved unaudited Q1 FY26 financial results, subject to limited review.
  • Director's Report and Management Discussion Report for FY26 were approved.
  • Appointment of Mrs. Vijaya Mani as Director approved, effective post-AGM.
  • Mr. N. K. Menon's reappointment as Whole time Director and CEO approved for one year.
  • 40th Annual General Meeting scheduled for September 22, 2026, at 2:30 PM.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Quarter ended
30th June, 2026
Year ended
31st March, 2026
Whole time Director & CEO Term
1 year w.e.f 1st October, 2026 to 30th September, 2027
40th Annual General Meeting Date
Tuesday, 22nd September, 2026
🏢 How This Affects the Company
📈
Business Impact
Formal approval of Q1 FY26 results and annual reports provides transparency to stakeholders. Management and director appointments signal continuity and corporate governance.
💰
Financial Impact
Unaudited Q1 FY26 financial results were presented, pending statutory auditor's limited review. These results will inform future financial performance tracking.
⚙️
Operational Impact
The appointment of a Whole Time Director and CEO for a further term ensures operational leadership continuity. The AGM date sets a timeline for member approvals.
⚠️
Risk Impact
Appointment of directors and CEO require member approval at the AGM, introducing a governance step. Limited review on unaudited results maintains inherent uncertainty until full audit.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders. Shareholders will vote on director appointments at the upcoming AGM.
👤
Who Is Affected
All shareholders will be affected by the approved financial results and management appointments that require member ratification at the AGM.
🔍
Management Signal
Management is signaling continuity in leadership and adherence to corporate governance timelines with these approvals and the scheduled AGM.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
40th Annual General Meeting on September 22, 2026.
Shareholder vote on director and CEO appointments.
Audited Q1 FY26 financial results post limited review.
LOW RISK Board meeting outcome is procedural; formal approvals are pending from members.
💡 Investor Takeaway
Colinz Laboratories Board approved unaudited Q1 FY26 results. Key management appointments for CEO and Director were approved, subject to member approval at the 40th AGM on September 22, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Board approved Directors Report for the year ended 31st March, 2026.
  • Board approved appointment of Mr. N. K. Menon as Whole time Director and CEO for a further term.
❓ Frequently Asked Questions
What did Colinz Laboratories' Board approve regarding financial results?
The Board approved the Un-Audited Financial Results for the quarter ended 30th June, 2026, which have undergone a 'Limited Review'.
When is Colinz Laboratories' 40th Annual General Meeting scheduled?
The 40th Annual General Meeting is scheduled for Tuesday, 22nd September, 2026, at 2:30 PM via video conference.
Who has been appointed as a new Director at Colinz Laboratories?
Mrs. Vijaya Mani has been approved for appointment as Director (Promoter & Non-Executive), subject to member approval at the AGM.
What is the term of Mr. N. K. Menon's reappointment as Whole time Director and CEO?
Mr. N. K. Menon's reappointment as Whole time Director and CEO is for a further term of 1 year, from October 1, 2026, to September 30, 2027.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.